Brief: Adamis Provides Update On Phase 2/3 Trial Of Tempol In COVID-19 Positive High-Risk Subjects

DMK Pharmaceuticals

21/09/2022 12:43

Sept 21 (Reuters) - Adamis Pharmaceuticals Corp  ADMP.O :
    * ADAMIS PROVIDES UPDATE ON THE PHASE 2/3 TRIAL OF TEMPOL IN
COVID-19 POSITIVE HIGH-RISK SUBJECTS
    * ADAMIS PHARMACEUTICALS - INTERIM DATA FROM PHASE 2/3
CLINICAL
TRIAL OF TEMPOL DID NOT DEMONSTRATE STATISTICAL SIGNIFICANCE OF
ITS PRIMARY ENDPOINT
    * ADAMIS PHARMACEUTICALS CORP - INTERIM DATA FROM PHASE 2/3
CLINICAL TRIAL OF TEMPOL DID NOT DEMONSTRATE STATISTICAL
SIGNIFICANCE OF ITS PRIMARY ENDPOINT
    * ADAMIS PHARMACEUTICALS CORP - INDEPENDENT DATA SAFETY
MONITORING
BOARD RECOMMENDS HALTING TRIAL
    * ADAMIS PHARMACEUTICALS CORP - DSMB DID NOTE THAT NO SAFETY
CONCERNS WERE IDENTIFIED IN SUBJECTS THAT RECEIVED TEMPOL
    * ADAMIS PHARMACEUTICALS CORP - HALTED TRIAL AND WILL NOW
EVALUATE
UNBLINDED DATA FROM TRIAL TO DETERMINE NEXT DEVELOPMENTAL STEPS
FOR TEMPOL
    * ADAMIS PHARMACEUTICALS - WILL NOW EVALUATE UNBLINDED DATA
FROM
TRIAL TO DETERMINE NEXT DEVELOPMENTAL STEPS FOR TEMPOL

Source text for Eikon:  ID:nGNX3VzPkX 
Further company coverage:  ADMP.O 

 ((Reuters.Briefs@thomsonreuters.com;))